Strategies for NSCLC: Clinical Pathways in the Era of Biomarker-Driven Care

Earn CME:

This webcast features a presentation by Dr. David Jackman discusses the latest efficacy and safety data, indications, and cost utility of novel therapies into optimal selection and non-small cell lung cancer (NSCLC) pathway placement strategies.

© 2019 NACCME, an HMP Company

CME,Continuing Medical Education,Education,Accreditation,Medical,Nurse,Residents-in-Training,Fellows,Physician,HMP CME,NACCME,oncology,oncologist,lung cancer,non-small cell lung cancer,NSCLC,novel therapy,therapy selection,therapeutic selection,clinical pathways,